drugset / Trial / NCT00516451
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to identify the maximum tolerated dose (MTD) of BMS-690514 once daily orally in Japanese subjects with advanced or metastatic solid tumors.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-690514 | Small molecule | 100 mg | Oral |
| Subject | BMS-690514 | Small molecule | 200 mg | Oral |
| Subject | BMS-690514 | Small molecule | 250 mg | Oral |
| Subject | BMS-690514 | Small molecule | 300 mg | Oral |